Who are Granite Bio's investors?

Granite Bio's investors include Novartis Venture Fund, Sanofi Ventures, Forbion, Versant Ventures.

How much funding has Granite Bio raised?

Granite Bio has disclosed $30M raised across 1 round.

Where is Granite Bio headquartered?

Granite Bio is headquartered in Basel, CH.

Granite Bio

Basel, CH · Founded 2021 · 26 employees on LinkedIn · 4 known investors

Find your way into Granite Bio

Paths you didn't know you had: your email and LinkedIn already hold routes to the Granite Bio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.

Biotech Medical Devices

Founders & leadership

Patrick Loustau President and Chief Executive OfficerPatrick Loustau previously served as chief business officer at Amolyt Pharma, which was acquired by Alexion, AstraZeneca Rare Disease in 2024, and as interim CEO of Zumbro Discovery and president of Zafgen. Earlier in his career he was SVP of global commercialization for cardiovascular and metabolics at Bristol-Myers Squibb in Princeton, New Jersey.

Investors · 4

Novartis Venture Fund✓ confirmed by Granite BioBasel · $5M – $25M

How we know: Novartis Venture Fund's portfolio page · the company's own site · pharmaceutical-technology.com · open dataset · 5k.vc investor directory · Not right? Tell us

Sanofi Ventures✓ confirmed by Granite BioCambridge · $5M

How we know: Sanofi Ventures's portfolio page · the company's own site · funding news · pharmaceutical-technology.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Forbion✓ confirmed by Granite BioNaarden

How we know: the company's own site · funding news · pharmaceutical-technology.com · open dataset · 5k.vc investor directory · Not right? Tell us

Versant Ventures✓ confirmed by Granite BioSan Francisco · $250K – $5M

How we know: the company's own site · funding news · investorsinhealthcare.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$30M disclosed across 1 round · 2025

$30MSeries AApr 2025 · 3 sources
Forbion (lead), Novartis Venture Fund (lead), Sanofi Ventures (lead), Versant Ventures (lead)
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Granite Bio Debuts With $100 Million of Capital - BioSpacebiospace.com · Nov 2025

Granite Bio Raises $100M in Fundingfinsmes.com · Apr 2025

Frequently asked questions

What does Granite Bio do?: Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.
Who are Granite Bio's investors?: Granite Bio's investors include Novartis Venture Fund, Sanofi Ventures, Forbion, Versant Ventures.
How much funding has Granite Bio raised?: Granite Bio has disclosed $30M raised across 1 round.
Where is Granite Bio headquartered?: Granite Bio is headquartered in Basel, CH.